Engineered brain‐targeting exosome for reprogramming immunosuppressive microenvironment of glioblastoma

Jun Yang, Yong Li, Shaoping Jiang, Yuxin Tian, Jun Zhang, Shuai Guo, Pengfei Wu, Jianan Li, Lin Xu, Wenpei Li, Yushu Wang, Huile Gao, Yuanyu Huang, Yuhua Weng, Shaobo RuanExploration 2024 · DOI

TL;DR

This paper introduces an innovative exosome-based delivery system (ACTE) engineered to overcome the blood-brain barrier (BBB) and target glioblastoma (GBM). By utilizing an acid-cleavable transferrin (Tf) modification, ACTE facilitates efficient BBB transcytosis and subsequent homing to GBM cells, delivering a combination therapy of doxorubicin (DOX) and siTGF-β to reprogram the immunosuppressive tumor microenvironment and enhance anti-cancer effects.

What Problem Does This Paper Address?

Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with a poor prognosis, largely due to its inherently immunosuppressive microenvironment and the formidable challenge of delivering therapeutic agents across the blood-brain barrier (BBB). Current treatments, including chemotherapy and immunotherapy, are significantly hampered by these issues. Specifically, RNA interference (RNAi) for targeted gene silencing, like that of TGF-β (a key immunosuppressive factor in GBM), faces limitations in brain delivery efficiency and specificity. This paper aims to address these challenges by developing a sophisticated exosome-based delivery system that can effectively cross the BBB, target GBM, and deliver a combination therapy to overcome both the physical barrier and the tumor's immunosuppressive defenses.

Methods

The core innovation lies in the engineering of exosomes for targeted brain delivery.

  • Metabolic Glycoengineering: GL261 cells were treated with Ac4ManNAz to introduce azide groups (N3) onto their surface, which were then incorporated into the secreted exosomes (Exo-N3).
  • Click Chemistry for Tf Decoration: An acid-cleavable transferrin (Tf) ligand, conjugated with DBCO (a click chemistry partner), was synthesized. This Tf-ligand was then attached to the N3-modified exosomes (Exo-N3) via a bioorthogonal click reaction to create the brain-targeting exosome system (ACTE). An acid-noncleavable version (ANTE) was also synthesized for comparison.
  • Drug Loading: Doxorubicin (DOX) and siTGF-β were loaded into ACTE via electroporation, resulting in the final therapeutic formulation, Ds@ACTE.
  • BBB Transcytosis Model: An in vitro BBB model using bEnd.3 cells was established to evaluate the transcytosis efficiency of engineered exosomes.
  • In Vivo Studies: Orthotopic GBM-bearing mice were used to assess biodistribution, targeting specificity, anti-glioma efficacy (survival, tumor growth, apoptosis), and immune response modulation.
  • Characterization Techniques: A suite of techniques including confocal laser scanning microscopy (CLSM), X-ray photoelectron spectroscopy (XPS), nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), western blotting, flow cytometry, RT-qPCR, and immunohistochemistry were employed to characterize the exosomes and evaluate their therapeutic effects.

Datasets

Not discussed in the paper. The study primarily relies on in vitro cell culture experiments and in vivo animal models.

Key Insights and Ideas

  • Acid-Cleavable Tf for BBB Transcytosis: The key innovation is the acid-cleavable linker for Tf. This allows Tf to bind to the transferrin receptor (TfR) on the BBB for initial uptake, but then detach within the acidic environment of the endosome/lysosome. This detachment is crucial for preventing exosome entrapment and promoting transcytosis across the BBB, a significant improvement over non-cleavable Tf modifications.
  • Dual Targeting Strategy: The system employs a two-pronged targeting approach: Tf-mediated recognition of TfR on the BBB for brain entry, followed by the intrinsic homing ability of GL261-derived exosomes to target GBM cells. This combination enhances specificity and accumulation at the tumor site.
  • Reprogramming Immunosuppressive Microenvironment: The siTGF-β component is critical for reversing the immunosuppressive nature of the GBM microenvironment. By downregulating TGF-β, the system promotes the infiltration and activation of anti-tumor immune cells (CD8+ T cells, CD4+ T helper cells) while reducing immunosuppressive regulatory T cells (Tregs).
  • Synergistic Chemo-Immunotherapy: The combination of DOX (cytotoxic chemotherapy) and siTGF-β (immunosuppression reversal) leads to a synergistic anti-tumor effect, enhancing both direct tumor cell killing and the body's own immune response against the cancer.

Key Results

  • Efficient BBB Transcytosis: Ds@ACTE demonstrated significantly enhanced in vitro BBB transcytosis compared to non-cleavable Tf-modified exosomes (Ds@ANTE) and unmodified exosomes (Ds@Exo).
  • Targeted GBM Accumulation: In vivo studies showed that ACTE preferentially accumulated in the GBM site, with a significantly higher G/B ratio compared to control groups.
  • Prolonged Survival: Mice treated with Ds@ACTE exhibited a significantly prolonged median survival time (39 days) compared to all other treatment groups, including free DOX&siTGF-β.
  • Reduced Tumor Growth and Increased Apoptosis: Ds@ACTE treatment led to a notable reduction in GBM cell proliferation (Ki67 staining) and a significant increase in apoptosis (TUNEL staining).
  • Immune Modulation: Ds@ACTE treatment significantly increased the proportion of CD8+ CTLs and CD4+ T helper cells in the tumor microenvironment and spleen, while decreasing Treg cells. It also led to a significant reduction in serum TGF-β levels.
  • Good Biocompatibility: Exosome-based formulations showed negligible cardiac toxicity and no significant changes in serum biochemical markers, indicating good biocompatibility.

Limitations and Future Work

  • Limitations: While promising, the study acknowledges that the Tf modification's role in targeting GBM cells after BBB crossing is less pronounced than its role in BBB transcytosis. The authors suggest that further optimization of the homing effect might be beneficial. The study also primarily uses a murine GBM model, and translation to human GBM would require further validation.
  • Future Work: The authors propose that this engineered exosome system provides a blueprint for designing more functional brain-targeting delivery systems. They also suggest exploring this approach as an effective combination therapy for GBM and potentially other CNS diseases. Further research could focus on optimizing the Tf detachment mechanism and exploring other exosome surface modifications for enhanced GBM targeting and therapeutic payload delivery.

Summary updated

Abstract

The immunosuppressive microenvironment of glioblastoma multiforme (GBM) severely impacts the response to various treatments, including systemic chemotherapy. Targeted reprogramming of immunosuppressive GBM microenvironment using RNA interference (RNAi) is largely restricted by poor brain delivery efficiency and targeting specificity. Herein, an acid-cleavable transferrin (Tf) decorated engineering exosome-based brain-targeting delivery system (ACTE) was proposed to efficiently deliver small interference RNA towards transform growth factor-β (siTGF-β) and doxorubicin (DOX) to GBM site for combination chemo-immunotherapy. The siTGF-β and DOX co-loaded ACTE, termed as DOX&siTGF-β@ACTE (Ds@ACTE), is designed to specifically recognize the Tf receptor (TfR) on the blood-brain barrier (BBB). Subsequently, Ds@ACTE undergoes acid-responsive detachment of Tf within lysosome of brain capillary endothelial cells, leading to the separation of DOX&siTGF-β@Exo (Ds@Exo) from the Tf-TfR complex and enhanced BBB transcytosis. After crossing BBB, the separated Ds@Exo can further target GBM cells via the homing effect. In vivo studies validated that Ds@ACTE significantly downregulated the TGF-β expression to reprogram the immunosuppressive microenvironment, and thereby reinforce the chemotherapeutic effect of DOX and DOX-induced anti-tumor immune response. The effectiveness of this strategy not only can provide thinking for designing a more intelligent brain-targeting system based on engineered exosomes but also explore an effective treatment regimen for GBM.
BibTeX
@inproceedings{yang2024engineered,
  author = {Jun Yang and Yong Li and Shaoping Jiang and Yuxin Tian and Jun Zhang and Shuai Guo and Pengfei Wu and Jianan Li and Lin Xu and Wenpei Li and Yushu Wang and Huile Gao and Yuanyu Huang and Yuhua Weng and Shaobo Ruan},
  title = {{Engineered brain‐targeting exosome for reprogramming immunosuppressive microenvironment of glioblastoma}},
  booktitle = {Exploration},
  year = {2024},
  doi = {10.1002/exp.20240039},
}
Figure